Insurance claims filed by SMA patients and families that have received treatment report complaints involving various body systems, implying that a true SMA disease rescue would target cells outside the central nervous system and reduce global defects caused by SMN insufficiency (Shababi et al., 2014; Lipnick et al., 2019). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.